Pharmaceutical

Risk adjusted net present value: What is the current valuation of Kissei Pharmaceutical’s Cretostimogene Grenadenorepvec?

Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).

Mar 13, 2024 - 18:29
Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Incyte’s Epaca...

Next Article

STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Botulinum battle heats up with FDA approving Daxxify for cervical dystonia

Botulinum battle heats up with FDA approving Daxxify fo...

Aug 14, 2023

Advocates expect Supreme Court Idaho abortion decision to fuel efforts to further restrict access

Advocates expect Supreme Court Idaho abortion decision ...

Jan 10, 2024

STAT+: House panel expected to mark up pandemic-preparedness bill next week

STAT+: House panel expected to mark up pandemic-prepare...

Jul 8, 2023